The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Tuberous Sclerosis Complex Research Program -- Clinical Translational Research Award
The Clinical Translational Research Award supports studies that will move promising, wellfounded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include studies moving from preclinical to clinical research (including a pilot clinical trial) and/or the reverse, analyzing human anatomical substances and/or data associated with clinical trials (such as correlative studies). Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest to the FY19 TSCRP.
Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. Preclinical studies may be appropriate but must include a clinical component. Projects that are exploratory and/or strictly animal research will not be considered for funding.
• Pre-Application Deadline: The pre-application deadline has been extended to July 9 2019:
• Application Submission Deadline:
May 9, 2019
Areas of Interest
The mission of the FY19 TSCRP is to fund exploratory, pioneering, and transformative science that promotes discoveries in TSC, from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public. Within this context, the FY19 TSCRP encourages applications that specifically address the critical needs of the TSC community in one or more of the following Focus Areas:
- Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
- Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures
- Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact through pharmacological or nonpharmacological interventions
- Advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinical pharmacokinetic/pharmacodynamic (PK/PD), patient selection and sample size determination, novel drug delivery, and treatment optimization
If the proposed research project does not address one or more of the FY19 TSCRP Focus Areas, justification that the proposed research project addresses an important problem or unmet need related to TSC research and/or patient care should be provided.
Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to apply. An eligible Principal Investigator, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY19 TSCRP Clinical Translational Research Award will not exceed $600,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.